EC
FULC icon

EcoR1 Capital’s Fulcrum Therapeutics FULC Stock Holding History

EcoR1 Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24M Buy
+6,549,866
New +$39.8M 1.17% 13
2020
Q3 		– Sell
-882,353
Closed -$16.1M – 57
2020
Q2 		$16.1M Buy
+882,353
New +$13.9M 1.19% 24

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

EcoR1 Capital's FULC Position: Q2 2026 in Review

EcoR1 Capital opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 6,549,866 shares worth $24M. The stake represents 1.17% of the portfolio and ranks #13 among its holdings. This is a return to the name: EcoR1 Capital previously reported a position in FULC as recently as Q2 2020.

EcoR1 Capital first reported a position in FULC in Q2 2020 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • EcoR1 Capital held 6,549,866 shares of Fulcrum Therapeutics worth $24M as of Q2 2026.
  • Fulcrum Therapeutics was a new EcoR1 Capital position in Q2 2026.
  • Fulcrum Therapeutics made up 1.17% of EcoR1 Capital's portfolio in Q2 2026, its #13 holding.
  • EcoR1 Capital first reported a position in Fulcrum Therapeutics in Q2 2020 and has held it in 2 quarters since.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.